After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Although Ozempic is Novo Nordisk's current crown jewel, Wegovy is quickly becoming a force on its own. Earlier this year, investors learned that sales of Wegovy rose 393% year over year in 2023.

On April 29, Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Hims & Hers stock soared on ...

Citing “unprecedented demand,” drugmaker Novo Nordisk said Thursday it expects supply restrictions on starter doses of the weight loss medicine Wegovy to persist into 2024, several months ...

Novo Nordisk, maker of the weight-loss drug Wegovy, said it would limit supply of starter doses as demand outpaces the company’s manufacturing capacity. CNN values your feedback 1.

Novo Nordisk’s type 2 diabetes drug Ozempic is semaglutide, but in a lower dose than Wegovy. These peptide drugs activate a receptor to increase levels of insulin in the blood.

LONDON, May 2 (Reuters) – Novo Nordisk has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have ...